Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 2,101–2,200 of 3,636
Modern principles of atherogenic dyslipidemia management in special groups of patients
Bubnova, M. G., & Евгеньевич, П. Л. (2020) · Cardiosomatics · doi:10.26442/22217185.2020.1.200089 · Cited by 4
Werba, J. P., Bonomi, A., Giroli, M., Amato, M., Vigo, L., Agrifoglio, M., Alamanni, F., Cavallotti, L., Kassem, S., Naliato, M., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa060 · Cited by 5
“a less intensive control of a single consolidated risk factor, such as LDL-C, for example.(3,4) This suggests that, although cases may have received higher doses and/or more potent drugs against specific risk factors”
BackgroundKao, Y.-C., Chen, T., Liu, C., Hwang, J., Hsiao, C.-C., Lin, Y., Mao, C., Hung, M., & Li, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-86090-9 · Cited by 4
Chaulin, A. M. (2021) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2020-98-11-12-739-744 · Cited by 5
Obesity 2021: Current Clinical Management of a Chronic, Serious Disease
Kushner (2021) · The Journal of Family Practice · doi:10.12788/jfp.0221 · Cited by 8
Evaluación del coste-efectividad de la utilización de los inhibidores de PCSK9
Civeira, F., & Pedro‐Botet, J. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.05.001 · Cited by 4
Gil-Núñez, A., Masjuán, J., Montaner, J., Castellanos, M., Segura, T., Cardona, P., Tembl, J. I., Purroy, F. F., Arenillas, J. F., & Palacio, E. (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.11.014 · Cited by 4
Nguy, J., Hitchen, S. A., Lan, N. S. R., Dwivedi, G., Larbalestier, R. I., Yeap, B. B., & Fegan, P. G. (2022) · Internal Medicine Journal · doi:10.1111/imj.15700 · Cited by 4
Zierfuss, B., Höbaus, C., Herz, C. T., Koppensteiner, R., Stangl, H., & Schernthaner, G.-H. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1827-7896 · Cited by 5
Sedykh, D. Y., Кашталап, В. В., Hryachkova, O. N., Петрова, Т. С., & Барбараш, О. Л. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-5030 · Cited by 6
Primary and secondary prevention of atherosclerotic cardiovascular disease: A case-based approach
Hariri, E. H., Hammoud, M. M. A., Nissen, S. E., & HAMMER, D. F. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21103 · Cited by 6
Alhajri, N., Rustom, M., Adegbile, A., Ahmed, W., Kilidar, S., & Afify, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911421 · Cited by 7
Dalal, J. J., Almahmeed, W. A., Krittayaphong, R., Nicholls, S. J., Soomro, K., & Yeo, K. K. (2023) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2022.24 · Cited by 4
Alirocumab in lipoprotein apheresis: A synergy for patients with high-Lp(a)
Sbrana, F., Bigazzi, F., Ripoli, A., & Pino, B. D. (2023) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2023.103660 · Cited by 4
Alzarroug, A. F., Gahtani, H. K. A., Algahtani, S., Alghamdi, H. K., Alhinti, M. F., Almutairi, K. A., & Algahtani, S. (2023) · Cureus · doi:10.7759/cureus.35514 · Cited by 5
“Recent studies have highlighted a significant efficacy in LDL-C reduction following evolocumab administration in ACS patients with the FOURIER clinical trial demonstrating substantial decreases in mortality ensuing from cardiovascular events, stroke, myocardial infarction (MI), and hospitalization due to adverse cardi…”
BackgroundInfluentialTransient very low LDL-C levels: a legacy effect for cardiovascular prevention?
Genest, J. J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad155 · Cited by 4
Zierfuss, B., Feldscher, A., Höbaus, C., Hannes, A., Koppensteiner, R., & Schernthaner, G.-H. (2023) · Scientific Reports · doi:10.1038/s41598-023-35073-z · Cited by 5
Deo, S. V., Al-Kindi, S. G., Virani, S. S., & Fremes, S. E. (2023) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2023.05.028 · Cited by 4
“162 Ezetimibe: Ezetimibe is a selective cholesterol inhibitor which targets the Niemann-Pick CI-Like 163 1 (NPC1L1; SLC65A2) (Figure S1) (29). In the IMPROVE-IT trial (2015), a combination of 164 moderate intensity simvastatin monotherapy versus combination therapy (moderate intensity 165 simvastatin + 10 mg oral dail…”
BackgroundLow Cholesterol Levels in Younger Heart Failure Patients May Predict Unfavorable Outcomes
Charach, L., Grosskopf, I., Galin, L., Guterman, I., Karniel, E., & Charach, G. (2023) · Medicina · doi:10.3390/medicina59071314 · Cited by 4
“The consensus is that increased mortality is associated with high LDL-c levels [1,2,6].”
BackgroundZafrir, B., Aker, A., Naoum, I., & Saliba, W. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.07.032 · Cited by 5
Lin, Z., Chen, Y., Xiao, Z., Xu, W., Chen, G., Huang, C., Feng, W., Xie, Z., Liao, W., Liao, Y., et al. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.06.003 · Cited by 4
25 years of lipid-lowering therapy: secular trends in therapy of coronary patients
Ratz, M., Vogel, J. B., Kuehrer, H., Säly, C., Mündlein, A., Vonbank, A., MADER, A., Fraunberger, P., Leiherer, A., & Drexel, H. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02365-x · Cited by 4
Impact of the COVID‐19 Pandemic on Conduct and Results of CLEAR Outcomes Trial
Singh, A., Laffin, L. J., Sarraju, A., Lincoff, A. M., Nicholls, S. J., Bloedon, L. T., Sasiela, W. J., Li, N., Robinson, P. L., Kelly, S., et al. (2024) · Clinical Cardiology · doi:10.1002/clc.24328 · Cited by 5
“IT [9], FOURIER [10], and ODYSSEY Outcomes trials [11].”
MethodSelf-citationTalviste, G., Leinsalu, M., Ross, P., & Viigimaa, M. (2024) · Medicina · doi:10.3390/medicina60091433 · Cited by 4
“The similarities and differences with other research are described in more detail below.”
ResultTackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Zamora, A., Masana, L., Plana, N., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.12.012 · Cited by 4
Zamora, A., Masana, L., Plana, N., et al. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2018.12.009 · Cited by 4
Bruckert, É., Kereiakes, D. J., Koren, M. J., Louie, M. J., Letierce, A., Miller, K., & Cannon, C. P. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.005 · Cited by 6
Orringer, C. E. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.04.009 · Cited by 5
Lipid Control Post Coronary Artery Bypass Graft: One Year Follow-Up of a Middle-Eastern Cohort
Atallah, B., Khaddage, R., Sadik, Z. G., et al. (2020) · Global Heart · doi:10.5334/gh.530 · Cited by 4
“It was shown in the simulation of impact that in a real-world scenario, 818 ASCVD patients in a cohort of 1000 would require treatment intensification with lipid-lowering therapies, resulting in 29 events avoided over 5 years [11, 15, 16].”
BackgroundDykun, I., Wiefhoff, D., Totzeck, M., Al‐Rashid, F., Jánosi, R. A., Hendricks, S., Rassaf, T., & Mahabadi, A. A. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00768-9 · Cited by 5
“In contrast, due to the higher absolute risk in elderly cohorts, the absolute risk reduction of preventive strategies is higher in this age group [6, 7, 20, 21].”
BackgroundCho, K. H., & Jeong, M. H. (2020) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2020.9.3.362 · Cited by 4
Armario, P., & Jericó, C. R. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.06.002 · Cited by 4
PCSK9 inhibitors and diabetes mellitus
Vohnout, B., Lisičanová, J., & Havranová, A. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.170 · Cited by 4
Blom, D. J., Ranjith, N., Joshi, P., Naidoo, P., van Tonder, A., Musa, M. G., Joshi, S., Leisegang, R. F., Trokis, J., Makan, H., et al. (2020) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2020-010 · Cited by 7
Cambet, T., Bochaton, T., Bel, F., Dérimay, F., Varillon, Y., Amaz, C., Bonnefoy‐Cudraz, E., Angoulvant, D., Charrière, S., Moulin, P., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa160 · Cited by 4
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 5
Screening for Autoantibodies in Type 1 Diabetes: A Call to Action
Петерс (2021) · The Journal of Family Practice · doi:10.12788/jfp.0223 · Cited by 11
Dyslipidemia in Women: Etiology and Management
Rajai, N., & Welty, F. K. (2021) · Stroke revisited · doi:10.1007/978-981-16-3923-4_16 · Cited by 6
Belgian data of ODYSSEY APPRISE: stringent LDL‐c targets are in reach when using all available tools
Verdickt, S., der Schueren, B. V., Vangoitsenhoven, R., Descamps, O. S., & Mertens, A. C. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14916 · Cited by 4
An update on emerging drugs for the treatment of hypercholesterolemia
Nelson, A. J., Bubb, K. J., & Nicholls, S. J. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.2009801 · Cited by 5
Yao, Y., Liu, J., Wang, B., Zhou, Z., Lu, X., Huang, Z., Deng, J., Yang, Y., Tan, N., Chen, S., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.817442 · Cited by 5
“Similarly, a post-hoc analysis of the ODYDDEY OUTCOMES study indicated that even after LDL-Ccorr was adjusted, a decrease of Lp(a) in alirocumab treatment group was associated with less MACE among ACS patients with a mean LDL-C of 40 mg/dL at 4-month follow-up (9, 22).”
MethodAssessment of CVD Risk Factors in Secondary Prevention after Ischemic Stroke Using the ICF
Lucki, M., Chlebuś, E., Wareńczak, A., Daroszewski, P., & Lisiński, P. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19063368 · Cited by 5
Taheri, F., Taghizadeh, E., Baniamerian, F., Rostami, D., Rozeian, A., Hayat, S. M. G., Jamialahmadi, T., Reiner, Ž., & Sahebkar, A. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220509040844 · Cited by 4
Co-repressing immunometabolic processes in atherosclerosis
Stein, S. (2022) · Cardiovascular Medicine · doi:10.4414/cvm.2021.02142 · Cited by 4
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome
Steg, P. G., Szarek, M. J., Valgimigli, M., Islam, M. S., Zeiher, A. M., Bhatt, D. L., Bittner, V., Chiang, C., Díaz, R., Goodman, S. G., et al. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.04.018 · Cited by 8
Self-citationProprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
Leong, D., & Wu, P. E. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.190107 · Cited by 4
Shi, Y., Su, Y., Liu, C., Tao, J., Fu, H., & Lu, C. (2020) · General Physiology and Biophysics · doi:10.4149/gpb_2019052 · Cited by 4
“Clinical trials proved that lipid-lowering drugs could significantly decrease the concentration of LDL-cholesterol, resulting in reduction in morbidity and mortality in cardiovascular disease patients and healthy people (Schwartz et al. 2018).”
BackgroundA Newly Approved Cholesterol Drug Joins the Lipid-Lowering Arsenal: Bempedoic Acid
Furer, J., Popova, O., & Plakogiannis, R. (2020) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2020.08.022 · Cited by 5
Li, C., Chen, J., Wei, S., Zhang, M., Chu, Y., Meng, F., Wang, J., Tang, J. T., Luo, J., Yu, Y., et al. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02189-x · Cited by 5
“3*Lp(a)) was used in several studies, as cholesterol account for 30%-45% of Lp(a) particle [18, 25].”
MethodRisk of remnants and remnant risk in peripheral artery disease
Hess, C. N., & Bonaca, M. P. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab815 · Cited by 5
Michos, E. D., & Ferdinand, K. C. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.9 · Cited by 8
Familial hypercholesterolaemia
Bovin, A., Kanstrup, H., & Mortensen, M. B. (2024) · Ugeskrift for Læger · doi:10.61409/v03240206 · Cited by 4
Grupos de alto rendimiento: una nueva actitud en la organización
LEAVITT, H. J., & Lipman-Blumen, J. (2000) · Harvard-Deusto business review · Cited by 4
Prolonged and Pronounced Low-Density Lipoprotein Cholesterol Lowering: The Gift That Keeps Giving
Shapiro, M. D. (2022) · Circulation · doi:10.1161/circulationaha.122.061727 · Cited by 4
Bowman, L. J., Weidinger, F. F., Albert, M. A., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.063378 · Cited by 4
Self-citationLipoprotein(a) and the Risk for Recurrent Ischemic Stroke Events
Rosenson, R. S., & Colantonio, L. D. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100559 · Cited by 4
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations
Stürzebecher, P. E., & Laufs, U. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000935 · Cited by 4
Bansal, M., Kasliwal, R. R., Chandra, P., Kapoor, R., Chouhan, N., Bhan, A., & Trehan, N. K. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.11.244 · Cited by 3
Carella, M. C., Carulli, E., Loizzi, F., Quarta, S., Freda, A., Basile, P., Amati, F., Dicorato, M. M., Latorre, M. D., Naccarati, M. L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072354 · Cited by 6
“High-intensity statin therapy is recommended and Ezetimibe, Be-mpedoic Acid and Pro-protein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors can be considered in patients with persistently elevated LDL cholesterol despite optimal statin therapy [115–117].”
Gim, D. H., Choi, I. Y., Ki, Y.-J., Kim, H. K., Kim, S. S., Park, K. H., Song, H., & Choi, D.-H. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.363 · Cited by 7
Lipoprotein(a) and aortic stenosis: Practical insights
Dimitriadis, K. S., Kyriakoulis, K. G., Pyrpyris, N., Beneki, E., Kamperidis, V., Κόλλιας, Α., Cenko, E., Aznaouridis, K. A., Aggeli, K. D., & Tsioufis, K. P. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104124 · Cited by 5
Lorenzatti, D., Greenberg, G. S., Filtz, A., Scotti, A., Jaspan, V. N., Park, C. M., Kalich, B. A., Jones, L. K., Kathe, N. J., Palo, K. E. D., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102075 · Cited by 4
Luo, B., Sun, Z., & Luo, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1584612 · Cited by 5
“Alirocumab showed a signi fi cant protective effect on coronary revascularization ( − 21%), but had a weaker impact on MI and stroke, in line with trends observed in the ODYSSEY OUTCOMES trial (Schwartz et al., 2021; Schwartz et al., 2018; Schwartz et al., 2020).”
Lupi, A., Baluci, M., Persampieri, S., Perversi, I., Presutti, D. G., Somaschini, A., Gaudio, G. V., Guasti, L., Ferrini, M., Corsini, A., et al. (2025) · Atherosclerosis Plus · doi:10.1016/j.athplu.2025.09.005 · Cited by 4
“While most of the current evidence on fast-track PCSK9 inhibition in ACS derives from clinical trials with monoclonal antibodies [4], some real-world data exist on the early initiation of other PCSK9 inhibitors, such as alirocumab and evolocumab, in ACS patients [7,22,23].”
Masson, W. M., Barbagelata, L., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.3.273 · Cited by 4
“40,41 In addition, inclisiran is a small interfering RNA that inhibits PCSK9 synthesis in hepatocytes, resulting in durable LDL-C reduction.”
Ruhela, N., Singla, A., Trivedi, Y. V., Ahmed, M., Chikatimalla, R., Gupta, S., & Jain, R. (2025) · Coronary Artery Disease · doi:10.1097/mca.0000000000001574 · Cited by 5
Lipoprotein(a) Lowering with Pelacarsen (TQJ230)
Sharma, K., Kattamuri, L. P. V., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x399029250923100015 · Cited by 6
Khattak, S., Ochoa-Ferraro, A. F., Khan, N., George, S., Khan, S. Q., Townend, J., Dawson, C., & Thomas, M. R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227946 · Cited by 6
Genedy, N., & Zouwail, S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.008 · Cited by 4
“34,35,36,37,38”
Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective
Hu, D., Deng, X., Feng, M., Zhang, X., He, Q., Wang, T., & Feng, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1708701 · Cited by 4
Gantz, A., Kapelanski‐Lamoureux, A., Rada, M., Krzywoń, L., Tsamchoe, M., Tsatoumas, A., Petrillo, S. K., Seidah, N. G., Lazaris, A., & Metrakos, P. P. (2025) · FEBS Journal · doi:10.1111/febs.70348 · Cited by 7
Brieger, D. B., Cullen, L., Briffa, T. G., et al. (2026) · The Medical Journal of Australia · doi:10.5694/mja2.70127 · Cited by 3
“For people already on intensive lipid-lowering therapy and ezetimibe but still with suboptimal LDL-C levels, the guideline recommends adding PCSK9 inhibitors (e.g., alirocumab, evolocumab and inclisiran) to further lower LDL-C and reduce cardiovascular events and mortality [73].”
Kataoka, Y., Nicholls, S. J., Kiyoshige, E., Nishimura, K., Puri, R., Kitahara, S., Murai, K., Mitsui, K., Tomishima, Y., Sawada, K., et al. (2026) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeag057 · Cited by 4
SU, H., Guo, X., Li, Q., Yuan, X., Wu, X., Zhao, Z., Kan, Y., Yang, Y., Fu, Z., Qi, Z., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1744830 · Cited by 4
“In the FOURIER and ODYSSEY OUTCOMES trials, evolocumab and alirocumab reduced major adverse cardiovascular events (MACE) by approximately 15% in high-risk statin-treated patients, consistent with the extent of LDL-C lowering (9, 10).”
Genetic factors contributing to atherosclerosis
Raddatz, M. A., Allayee, H., & Lusis, A. J. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001286 · Cited by 4
Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins
Brandts, J., Verket, M., Zambon, A., Marx, N., Müller-Wieland, D., & Federici, M. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03166-4 · Cited by 4
“The FOURIER and ODYS-SEY OUTCOMES trials reported relative risk reductions in CV events of 17% and 16%, respectively [44, 46], with greater absolute benefits observed in people with diabetes [47, 48].”
Ginsberg, H. N., & Bornfeldt, K. (2026) · Circulation Research · doi:10.1161/circresaha.125.327267 · Cited by 4
New targets for treating hypertriglyceridemia
Parhofer, K. G. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000714 · Cited by 5
“LDL-cholesterol translates into cardio-vascular benefit as it was shown in the PCSK9-inhibitor outcome trials [8,9].”
BackgroundThe management of cardiovascular disease risk in patients with rheumatoid arthritis
Ahmed, O., Krishnamurthy, V., Kaba, R. A., & Tahir, H. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2076594 · Cited by 6
Sex disparities and dyslipidemic control in a coronary rehabilitation program
Proença, T., Pinto, R. A., Carvalho, M. M., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.11.025 · Cited by 3
Real-World Use of Alirocumab: Experience from a Large Healthcare Provider
Elis, A., Cohen, C. M., & Chodick, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031084 · Cited by 4
“This is opposed to the two leading CVO studies, FOURIER, and ODYSSEY OUTCOMES [8,10] as well as most previous real-world studies.”
ResultThe Role of Genetics in Advancing Cardiometabolic Drug Development
Abou-Karam, R., Cheng, F., Gady, S., & Fahed, A. C. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01195-6 · Cited by 4
Sloot, R., Breskin, A., Colantonio, L. D., Allmon, A. G., Yu, Y., Sakhuja, S., Chen, L., Muntner, P., Brookhart, M. A., & Dhalwani, N. N. (2024) · Epidemiology · doi:10.1097/ede.0000000000001730 · Cited by 4
Shen, F., Chu, C., Chen, J., Kuo, C., Hsu, C., Lin, C., Sheen, Y., Su, S., Tien, K., Lu, C., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14222 · Cited by 4
“The ODYSSEY OUTCOMES trial focused on alirocumab and demonstrated a 15% reduction in composite primary endpoints, with greater bene fi ts observed in patients with diabetes mellitus 18 .”
MethodNasso, G., Vignaroli, W., Amodeo, V., Bartolomucci, F., Larosa, C., Contegiacomo, G., Demola, M. A., Girasoli, C., Valenzano, A., Fiore, F., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13102987 · Cited by 4
“Beyond their primary function of lowering LDL cholesterol levels, statins, hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also contribute to cardioprotection through their anti-inflammatory, antioxidant, and immunomodulatory properties [23–25].”
BackgroundGarcía-Gil, M., Alves‐Cabratosa, L., Cunillera, O., Blanch, J., Martí‐Lluch, R., Ponjoan, A., Ribas‐Aulinas, F., Tornabell‐Noguera, È., Zacarías‐Pons, L., Domínguez‐Armengol, G., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14258 · Cited by 3
“…for unlimited lowering of the LDL-C levels stems from Mendelian randomization studies, 4,5 several meta-analyses 6–8 and posterior clinical trials 9–11 The trials examined populations in primary or secondary cardiovascular prevention and compared people treated with lipid-lowering medications…”
Prediction of Cardiovascular Disease Risk in the General Population: A GSA-ELM Approach
Lohbare, S., Alleema, N. N., Praveena, S., Patil, H., Rajalakshmi, S., & Lakineni, P. K. (2024) · International Conference on Electronics, Computing, Communication and Control Technology (ICECCC) · doi:10.1109/iceccc61767.2024.10593856 · Cited by 5
Takahashi, Y., Morimoto, T., Iekushi, K., & Arai, H. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64848 · Cited by 5
He, W. B., Jape, D., Nanayakkara, S., & Shaw, J. A. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2024.07.012 · Cited by 3
Deconinck, O. G., Sharman, J. E., Bishop, W., Lees, C. F., Dare, L., Hardikar, A., Fenton, C., Pointon, T., Watts, G. F., & Black, J. A. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2024.08.001 · Cited by 4
Wierzbicki, A. S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2444986 · Cited by 10
“The endpoint studies of licensed antibody PCSK9 inhibitors (FOURIER [35], ODYSSEY-outcomes [36]) were”
Differential lipid impact on mortality in patients undergoing CABG versus PCI
Yuan, X., Zhang, L., Li, X., Chen, K., Chu, Q., Chen, L., & Hu, S. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119141 · Cited by 3
Buciu, I. C., Țieranu, E. N., Pîrcălabu, A. Ş., Zlatian, O. M., Donoiu, I., Cioboată, R., Militaru, C., Militaru, S., & Botezat, M. M. (2025) · Romanian Journal of Morphology and Embryology · doi:10.47162/rjme.65.4.07 · Cited by 6
Likozar, A. R., Levstek, T., Karun, T., Podkrajšek, K. T., Zupan, J., & Šebeštjen, M. (2025) · European journal of medical research · doi:10.1186/s40001-025-02398-6 · Cited by 3
Wargny, M., Goronflot, T., Piriou, P., Pouriel, M., Bastien, A., Prax, J., Leux, C., Riche, V.-P., Trochu, J., Béliard, S., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101638 · Cited by 6
Mak, Y. H., Chua, F., Koh, X. H., Tan, V. H., Lee, Z. H., Lam, A., Tong, K. L., Yeo, C., Chow, W., & Loh, W. J. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2024-172 · Cited by 3
Prabhakar, A. P., Vedamurthy, D., & Kalra, D. K. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00764-x · Cited by 4
“The FOURIER and ODYSSEY OUTCOMES trial showed that the PCSK9 monoclonal antibodies safely and effectively lower LDL-C and cardiovascular events in patients with stable and acute ASCVD on background high-intensity statin therapy [50, 51].”
Gomes, L. L. A., Faden, D. F., Xie, L., Chambers, S., Stone, C. J., Werth, V. P., & Williams, K. J. (2025) · Lupus Science & Medicine · doi:10.1136/lupus-2024-001160 · Cited by 3
Ma, H., Ma, W., Liu, Y., Chen, L., & Ding, P. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26980 · Cited by 3
“In the ODYSSEY OUTCOMES trial, we found that the absolute reduction in the risk of the composite primary endpoint with alirocumab was greatest in patients with baseline LDL-C ≥ 100 mg/dL [1].”
Influential
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

